Korean Market
EXCH
Jeil Pharmaceutical
★

Jeil Pharmaceutical Files 2025 Corporate Governance Report: Improvements in Electronic Voting but No Dividends and Persistent Non-Compliance

 
PERI
Jeil Pharmaceutical
★

Q1 Consolidated Revenue Down 20%, Operating Profit Plunges 93%... Treasury Shares Fully Sold

 
PERI
Jeil Pharmaceutical
★

Jeil Pharma Q1 2026: Consol. Revenue -20%, Op. Profit -93%; Subsidiary Oncovic Strong

 
OWNR
Jeil Pharmaceutical
★

Submission of Major Shareholding Report (No Holdings Data)